Abdul Latif Jameel Health and Cureleads announce new strategic collaboration for UAE distribution of innovative health care products and services

Abdul Latif Jameel Health and Cureleads announce new strategic collaboration for UAE distribution of innovative health care products and services

- Founded in 2019, Cureleads works to transform patient lives across the MENA region by leading the path to cure specialty and rare diseases, led by its highly profiled industry leader founders.

Dubai UAE: Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, and Cureleads, a Dubai, UAE and Beirut, Lebanon based pharmaceutical and medicinal distribution and marketing business working throughout the Middle East and North Africa, have announced a new agreement for the distribution of Butterfly Network, Inc.’s Butterfly iQ+ ultrasound solution in the UAE.

The innovative Butterfly iQ+[1] is the world's first single probe, whole-body handheld ultrasound solution that brings the power of ultrasound into assessment, diagnosis and treatment processes.

As part of its new agreement with Abdul Latif Jameel Health, Cureleads will register Butterfly iQ+ in the United Arab Emirates – already widely considered the healthcare hub for the Middle East – and start commercial sales in December 2022, bringing the technology to potentially more than 26,000 medical doctors practicing in public and private hospitals and facilities across the Emirates[2].

World Health Organization data suggests that over 4.7 billion people around the world lack access to medical imaging[3], from underserved communities in the United States to remote